Barclays’s Anixa Biosciences ANIX Stock Holding History

Barclays’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$30	–	5219
2025 Q3	$30	Buy	+9	New	+$28	﹤0.01%	5338
2021 Q3	–	Sell	-2,532	Closed	-$10K	–	4733
2021 Q2	$10K	Sell	2,532 -7,466	-75%	-$31.8K	﹤0.01%	4621
2021 Q1	$47K	Buy	+9,998	New	+$47.8K	﹤0.01%	4211
2020 Q1	–	Sell	-1	Closed	–	–	6113
2019 Q4	$0	Buy	+1	New	+$4	﹤0.01%	6316
2018 Q2	–	Sell	-15	Closed	–	–	6941
2018 Q1	$0	Buy	+15	New	+$58	﹤0.01%	7023

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Barclays's ANIX Position: Q4 2025 in Review

Barclays sold out of Anixa Biosciences (ANIX) in Q4 2025, closing a stake of 9 shares — an estimated $30 sold.

Barclays first reported a position in ANIX in Q1 2018 and held it in 5 quarters. The position peaked at $47K in Q1 2021. 71 funds tracked by Wall St. Rank hold ANIX as of Q4 2025.

Barclays reported no remaining Anixa Biosciences position as of Q4 2025 after selling out during the quarter.
Barclays sold 9 Anixa Biosciences shares in Q4 2025, an estimated $30.
Barclays first reported a position in Anixa Biosciences in Q1 2018 and held it in 5 quarters.
Barclays's Anixa Biosciences position peaked at $47K in Q1 2021.
71 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.